Completed × Ovarian Neoplasms × Gastrointestinal × Clear all Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1 Completed
62 enrolled 17 charts
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Phase NA Completed
121 enrolled 16 charts
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
215 enrolled 30 charts
MiGHT
Phase NA Completed
831 enrolled
CATALYST
Phase NA Completed
50 enrolled
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
Completed
64 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Phase 1 Completed
42 enrolled
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Phase 1/2 Completed
18 enrolled
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Phase 2 Completed
25 enrolled 11 charts
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
Completed
22 enrolled
INOVOLINE
Phase NA Completed
101 enrolled
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
83 enrolled 21 charts
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
FIDURA
Phase 3 Completed
354 enrolled
AMPLIFY-201
Phase 1 Completed
25 enrolled 15 charts
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
OLAP
Completed
661 enrolled
KEYVIBE-005
Phase 2 Completed
613 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Completed
7 enrolled
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
PRIORITY
Completed
346 enrolled 9 charts
P-COC
Phase NA Completed
60 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
PREFER
Completed
1,429 enrolled
ACTolog
Phase 1 Completed
38 enrolled
PRISMS
Phase NA Completed
46 enrolled 19 charts
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Abdominopelvic Cancer Prehabilitation
Phase NA Completed
66 enrolled
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 1 Completed
279 enrolled
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1/2 Completed
26 enrolled 14 charts
IVY
Phase 1 Completed
353 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled
Dragon
Phase NA Completed
52 enrolled
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Phase 1 Completed
73 enrolled 18 charts